These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 17695515

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Renée N, Iliadis A, Fischel JL, Ciccolini J.
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [Abstract] [Full Text] [Related]

  • 8. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
    Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA.
    Cancer; 2011 Sep 15; 117(18):4125-31. PubMed ID: 21387266
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M, Yamaguchi Y, Moriya Y, Sawada N, Yasuno H, Kondoh K, Evans DB, Mori K, Hayashi S.
    Oncol Rep; 2012 Feb 15; 27(2):303-10. PubMed ID: 22076074
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.
    Cancer Chemother Pharmacol; 2010 Jul 15; 66(2):269-76. PubMed ID: 19904537
    [Abstract] [Full Text] [Related]

  • 12. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
    Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C.
    Eur J Cancer; 2012 Nov 15; 48(17):3140-9. PubMed ID: 22640829
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V, Fotiou S, Gennatas S, Gennatas C.
    Anticancer Res; 2010 Jul 15; 30(7):3051-4. PubMed ID: 20683054
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T, Ito Y, Takahashi S, Tokudome N, Iwase T, Hatake K.
    Cancer Chemother Pharmacol; 2008 Jun 15; 62(1):159-64. PubMed ID: 17882419
    [Abstract] [Full Text] [Related]

  • 15. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
    Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group (KBCSG).
    Cancer Chemother Pharmacol; 2008 May 15; 61(6):989-95. PubMed ID: 17641893
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.
    Cancer Chemother Pharmacol; 2010 Mar 15; 65(4):755-63. PubMed ID: 19669644
    [Abstract] [Full Text] [Related]

  • 17. Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.
    Susnjar S, Bosnjak S, Radulovic S, Stevanovic J, Gajic-Dobrosavljevic M, Kreacic M.
    J BUON; 2007 Mar 15; 12(2):189-96. PubMed ID: 17600871
    [Abstract] [Full Text] [Related]

  • 18. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG, Melnik MK, Piette F, Geyer CE, Mamounas EP, Wolmark N.
    Clin Breast Cancer; 2011 Aug 15; 11(4):228-34. PubMed ID: 21684812
    [Abstract] [Full Text] [Related]

  • 19. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
    Uhlmann C, Ballabeni P, Rijken N, Brauchli P, Mingrone W, Rauch D, Pestalozzi BC, Rochlitz C, Aebi S, Swiss Group for Clinical Cancer Research, Swiss Institute for Applied Cancer Research.
    Oncology; 2004 Aug 15; 67(2):117-22. PubMed ID: 15539915
    [Abstract] [Full Text] [Related]

  • 20. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
    Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.
    Eur J Cancer; 2012 Mar 15; 48(4):482-91. PubMed ID: 22257791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.